Philippe Denoel

Philippe Denoel

Auto-generated profile, based on publicly available information

Philippe Denoel

GSK, Rixensart, Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2024 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Open access
EKEili Klein
Eili Klein
IIIsabella Impalli
Isabella Impalli
SPSuprena Poleon
Suprena Poleon
PDPhilippe Denoel
Philippe Denoel
MCMariateresa Cipriano
Mariateresa Cipriano
ANArindam Nandi
Arindam Nandi
Antibiotic resistance is a global public health threat. Many factors contribute to this issue, with human antibiotic consumption being significant among them. Analyzing trends and patterns in consumption can aid in developing policies to mitigate the burden of antimicrobial resistance and global disparities in access to antibiotics. Using pharmaceutical sales data licensed from IQVIA, we estimate national-level trends in antibiotic consumption in 67 countries during 2016–2023 and analyze the effects of economic growth and the COVID-19 pandemic. Finally, we estimate global human consumption and project growth through 2030 assuming current trends. We find that estimated antibiotic consumption in reported countries increased 16.3% from 29.5 to 34.3 billion defined daily doses (DDDs) from 2016 to 2023, reflecting a 10.6% increase in the consumption rate from 13.7 to 15.2 DDDs per 1,000 inhabitants per day. Increases were most pronounced in upper-middle- and lower-middle-income countries. While the COVID-19 pandemic significantly reduced consumption globally, this was most pronounced in high-income countries, and in these countries, reductions in antibiotic use in 2020 were sharper, and lasted longer, than in other countries. By 2030, we project that, without reductions in rapidly developing nations, such as investments to improve infrastructure, particularly water and sanitation, along with improved access to vaccination, global antibiotic consumption will increase by 52.3% from an estimated 49.3 billion in 2023 to 75.1 billion DDDs.

16 April 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
Gianmarco GasperiniGianmarco Gasperini
Gianmarco Gasperini
NBNorman Baylor
Norman Baylor
SBSteve Black
Steve Black
DBDavid E. Bloom
David E. Bloom
JCJakob Cramer
Jakob Cramer
RRRino Rappuoli
Rino Rappuoli
Artificial intelligence (AI) has already transformed vaccine antigen design and could transform the entire vaccinology pipeline, including immune responses and emerging infectious disease prediction, manufacturing and regulatory processes, clinical trial design and implementation, and vaccine access and equity. However, realizing the promise of AI for vaccinology requires more high-quality data.

14 October 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
Gianmarco GasperiniGianmarco Gasperini
Gianmarco Gasperini
SPSilvia Rossi Paccani
Silvia Rossi Paccani
KOKaren O’DWyer
Karen O’DWyer
DADavid M. Aanensen
David M. Aanensen
DADarius Armstrong-James
Darius Armstrong-James
EGEnnio De Gregorio
Ennio De Gregorio
Integrated strategies to combat antibiotic-resistant bacteria and fungi require innovative commercial models, new discovery platforms, standardized genomic surveillance, and streamlined clinical trials. Machine learning and other new technologies will accelerate the development of diagnostics and therapeutics (small molecules, antibodies, and vaccines) to combat antimicrobial resistance. Next-generation approaches should align societal impact with investment to ensure rapid global public health gains.